Objective: Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups. Results: The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose. Conclusions: These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.
【저자키워드】 SARS-CoV-2, vaccination, ovarian cancer, PARP inhibitors, 【초록키워드】 COVID-19, Treatment, therapy, Infection, SARS-CoV-2 immunity, Cohort, COVID-19 vaccination, anti-SARS-CoV-2 antibody, Patient, PARP, General population, inhibitor, Precaution, co-morbidities, SARS-CoV-2 neutralizing antibody, demographics, cancer patient, two groups, second dose, NAbs, significantly lower, enrolled, the patient, receiving, treated, provide, reduce, healthy volunteer, 【제목키워드】 COVID-19, response, PARP,